1. Home
  2. Companies
  3. TLX
  4. Material Events

Telix Pharmaceuticals (ASX:TLX) — Material Events

ASX:TLX · 20 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major 7 articles Significant 13 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Major Score 90+
7
Telix bets US$1.65 billion on ITM and a faster route into radiopharmaceutical therapiesHigh
Telix proposes US$1.65B acquisition of ITM to build integrated radiopharmaceutical platform
21 Sept 2026 ·Mergers and Acquisitions ·Unexpected ·98
Telix Pharmaceuticals Posts $38.3M Profit on 22% Revenue Surge, Boosts R&D and Partners with RegeneronHigh
Telix Pharmaceuticals reports H1 2026 profit of $38.3M on 22% revenue growth, expands R&D and partners with Regeneron
20 Aug 2026 ·Appendix 4D and Interim Financial Report ·95
Telix Wins First FDA Approval for Glioma FET-PET Imaging DrugHigh
FDA approves Telix's Pixclara as first glioma-specific FET-PET imaging drug in the US
14 Sept 2026 ·Regulatory Approval ·95
Significant Score 75–89
13
Telix Resubmits FDA Application for Brain Cancer Imaging Agent Pixclara®Medium
Telix Resubmits NDA for Brain Cancer Imaging Agent TLX101-Px to FDA with Additional Data
16 Mar 2026 ·Regulatory Update ·85
Telix Secures FDA Nod to Expand ProstACT Phase 3 Prostate Cancer TrialMedium
Telix secures FDA alignment to advance ProstACT Global Phase 3 prostate cancer trial
2 July 2026 ·Clinical Trial Update ·85
Telix Reports 11% Q1 Revenue Growth and Advances Prostate Cancer Therapy TrialsMedium
Telix reports strong Q1 revenue growth, advances prostate cancer therapy trials, and reaffirms FY 2026 guidance
7 Apr 2026 ·Quarterly Business Update ·85
Telix Advances Brain Cancer Imaging with European Filing for TLX101-PxMedium
Telix Submits European Marketing Authorization Application for Brain Cancer Imaging Agent TLX101-Px
18 Feb 2026 ·Regulatory Filing ·85
Telix Completes Phase 3 BiPASS Enrollment, Secures FDA Alignment for Prostate Cancer ImagingMedium
Telix Completes Phase 3 BiPASS Enrollment and Aligns with FDA on NDA Pathway for Prostate Cancer Imaging
2 Sept 2026 ·Clinical Trial Update and Regulatory Announcement ·85
FDA Accepts Telix’s NDA for Glioma Imaging Agent TLX101-Px with September Review TargetHigh
FDA Accepts NDA for Telix's Glioma Imaging Agent TLX101-Px with Approval Target in September 2026
10 Apr 2026 ·Regulatory Update ·85
Telix Scores Regulatory Nod to Bring Illuccix Prostate Imaging to ChinaMedium
Telix's Illuccix NDA accepted by Chinese regulator, backed by positive Phase 3 data
20 Jan 2026 ·Regulatory Announcement ·85
Telix Advances ProstACT Phase 3 Trial with First Patient Dosed in Global ExpansionMedium
Telix Doses First Patient in Expanded Phase 3 ProstACT Trial for Prostate Cancer
8 Dec 2025 ·Clinical Trial Update ·85
Telix Launches US$550 Million Convertible Bonds to Refinance Debt and Fund GrowthMedium
Telix Pharmaceuticals launches US$550 million convertible bonds offering to refinance existing debt
14 Apr 2026 ·Capital Raising ·85
Telix Advances With Strong Illuccix Data and FDA Resubmission ProgressMedium
Telix reports positive Illuccix China Phase 3 data and FDA resubmission progress for TLX101-CDx and TLX250-CDx
22 Dec 2025 ·Clinical Trial Update and Regulatory Filing Update ·85
Telix’s ProstACT Phase 3 Part 1 Confirms Safety, Paving Way for Global ExpansionMedium
Telix's ProstACT Phase 3 Part 1 meets safety goals; Part 2 enrollment underway globally
10 Mar 2026 ·Clinical Trial Update ·85
Telix gains FDA Fast Track status for pre-biopsy prostate imaging programMedium
Telix wins FDA Fast Track designation for pre-biopsy prostate cancer imaging program
30 Sept 2026 ·Regulatory Milestone ·82
Telix Advances ProstACT Phase 3 Prostate Cancer Trial to Part 2 with Global ApprovalsMedium
Telix Advances ProstACT Phase 3 Prostate Cancer Trial to Part 2 with Global Regulatory Approvals
17 Dec 2025 ·Clinical Trial Update ·80
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.

Market Mentions 22 - appeared in market wrap coverage

These are market wrap articles where Telix Pharmaceuticals (ASX:TLX) was mentioned. They reflect broader market coverage, not company-specific announcements.

Market Wrap - Week 39 (21 Sept -> 25 Sept) 2026
26 Sept 2026
Wrap
Healthcare Wrap - Week 39 (21 Sept -> 25 Sept) 2026
26 Sept 2026
Wrap
Market Wrap - Week 38 (14 Sept -> 18 Sept) 2026
19 Sept 2026
Wrap
Market Wrap - Week 36 (31 Aug -> 4 Sept) 2026
5 Sept 2026
Wrap
Healthcare Wrap - Week 36 (31 Aug -> 4 Sept) 2026
5 Sept 2026
Wrap